Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR is hard to do profitably.

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Beans are a key food at the dietary level, boasting high nutritional value and constituting the most directly consumed legume ...

While billions pour into pharmaceutical biotech, officials and experts warn there’s much less private investment in products more relevant to the military, like body armor materials, anti-corrosion ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report), with a price ...

On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO, Samarth Kulkarni. Thank you so much, Sam. Yeah. Happy to do that. I think we’ve been around as ...

CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...